[Infliksimab in therapy of inflammatory bowels diseases].
In last decade there were an increase in patients with inflammatory bowel disease (IBD) - Crohn's disease (CD) and ulcerative colitis (UC). To achieve remission of IBD usually was used various combinations of 5-ASK drugs, glucocorticoids and cytostatics, but positive dynamics of the patients cannot achieve. In this regard some prospects assigned to infliksimabom therapy. You can find results of Remikeyd therapy in patients with Crohn's disease and ulcerative colitis. We showed that all cases achieved positive dynamics within the IBD, which allowed him to recommend as an effective tool in the form of monotherapy for one year.
Kniazev
O V
OV
Lazebnik
L B
LB
Ruchkina
I N
IN
Tsaregorodtseva
T N
TN
Parfenov
A I
AI
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003093:Colitis, Ulcerative / Q000097:blood / Q000188:drug therapy*; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab